Basit öğe kaydını göster

dc.contributor.authorHaslam, Collette
dc.contributor.authorPanicker, Jalesh N.
dc.contributor.authorDunya, Cansu Polat
dc.contributor.authorTÜLEK, Zeliha
dc.contributor.authorUchiyama, Tomoyuki
dc.date.accessioned2022-02-18T08:59:34Z
dc.date.available2022-02-18T08:59:34Z
dc.date.issued2020
dc.identifier.citationDunya C. P. , TÜLEK Z., Uchiyama T., Haslam C., Panicker J. N. , "Systematic review of the prevalence, symptomatology and management options of sexual dysfunction in women with multiple sclerosis", NEUROUROLOGY AND URODYNAMICS, cilt.39, sa.1, ss.83-95, 2020
dc.identifier.issn0733-2467
dc.identifier.othervv_1032021
dc.identifier.otherav_0f359816-03f7-44ea-a0aa-df40ff855520
dc.identifier.urihttp://hdl.handle.net/20.500.12627/176277
dc.identifier.urihttps://doi.org/10.1002/nau.24232
dc.description.abstractAims Sexual dysfunction (SD) is highly prevalent in women with multiple sclerosis (MS), however little is known about treatment options. The aim of this paper is to review the prevalence, symptomatology, and management options of sexual dysfunction in women with MS. Methods The Cochrane Database of Systematic Reviews, MEDLINE, EMBASE, CINAHL, AMED, PsycINFO, PEDro, Database of International Rehabilitation Research, Occupational Therapy Systematic Evaluation of Evidence, , and Current Controlled Trials databases were searched. No limitations were placed on the date. A critical appraisal of the literature on SD in women with MS was performed according to the PRISMA statement. Two reviewers screened and extracted data. Study quality was evaluated using a standardized tool. Results A search of 12 databases identified 61 relevant studies (33 observational, 14 case-control, 4 follow up, 10 interventional). Significant variability in the prevalence of SD and questionnaires used to evaluate SD were observed. The most commonly reported sexual difficulties were problems with desire, arousal, and orgasm. Different demographics and MS-related characteristics were found to contribute to SD. Few studies have evaluated interventions for treating SD, and bias was high because of the weak quality of trial designs. Conclusions SD in women with MS is multidimensional, comparable in prevalence with other neurological disorders and increases with advancing disease. Studies evaluating practical strategies and pharmacological interventions are few, and properly designed trials using MS-specific validated outcome measures of SD are required to inform evidence-based treatment options for this high impact MS-related dysfunction.
dc.language.isoeng
dc.subjectNephrology
dc.subjectUrology
dc.subjectHealth Sciences
dc.subjectİç Hastalıkları
dc.subjectNefroloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.titleSystematic review of the prevalence, symptomatology and management options of sexual dysfunction in women with multiple sclerosis
dc.typeMakale
dc.relation.journalNEUROUROLOGY AND URODYNAMICS
dc.contributor.departmentUniversity Of London , ,
dc.identifier.volume39
dc.identifier.issue1
dc.identifier.startpage83
dc.identifier.endpage95
dc.contributor.firstauthorID3387620


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster